IDDI at ASCO Meeting
June 2, 2017 — June 7, 2017
Chicago, IL, USA
IDDI presents a Poster at ASCO Meeting: A phase II trial of the CDK4/6 inhibitor Palbociclib (P) as single agent or in combination with the same endocrine therapy (ET) received prior to disease progression, in patients (pts) with hormone receptor positive (HR+), HER2 negative (HER2–) metastatic breast cancer (mBC) (TREnd trial). Malorni L, Curigliano G, Minisini A, Cinieri S, Tondini C, De Placido S, Pavesi L, Martignetti A, Criscitiello C, Puglisi F, Pestrin M, Sanna G, Moretti E, Risi E, Biagioni C, Boni L, Baldari D, Buyse M, Biganzoli L, Di Leo A.
- Sat, Jun 03 : 1:15 PM – 4:15 PM
- Location: Hall D1
- Track(s): Breast Cancer—Metastatic
The ASCO Annual Meeting offers informative educational and scientific sessions that highlight the latest in cancer care treatments. The ASCO Annual Meeting brings together more than 30,000 oncology professionals from around the world to discuss state-of-the-art treatment modalities, new therapies, and ongoing controversies in the field.
